Table 1.
Demographic, operative, postoperative, and pathological characteristics of the study cohort.
| Variable | All Patients (n=679) | Direct R0 (n=598) | R1 (n=55) | Converted R0 (n=26) | P |
|---|---|---|---|---|---|
| Sex | |||||
| Male | 458 (67.5%) | 404 (67.6%) | 35 (63.6%) | 19 (73.1%) | 0.690 |
| Female | 221 (32.5%) | 194 (32.4%) | 20 (36.4%) | 7 (26.9%) | |
| Age, years | 63.8 | 64.1±0.5 | 61.0±1.7 | 63.2±2.4 | 0.198 |
| Tumor site | |||||
| GEJ | 258 (38.1%) | 218 (36.6%) | 21 (38.2%) | 19 (73.1%) | <0.001 |
| Proximal stomach | 53 (7.8%) | 43 (7.2%) | 7( 12.7%) | 3 (11.5%) | |
| Body | 180 (26.6%) | 166 (27.9%) | 12 (21.8%) | 2 (7.7%) | |
| Distal | 145 (21.4%) | 136 (22.8%) | 8 (14.5%) | 1 (3.8%) | |
| Whole stomach | 15 (2.2%) | 9 (1.5%) | 5 (9.1%) | 1 (3.8%) | |
| Gastric stump | 26 (3.8%) | 24 (4.0%) | 2 (3.6%) | 0 (0.0%) | |
| Operation type | |||||
| Transhiatal extended | 282 (41.5%) | 235 (39.3%) | 27 (49.1%) | 20 (76.9%) | <0.001 |
| Total | 296 (43.6%) | 272 (45.5%) | 21 (38.2%) | 3 (11.5%) | |
| Subtotal | 61 (9.0%) | 59 (9.9%) | 2 (3.6%) | 0 (0.0%) | |
| Resection of remnant stomach | 30 (4.4%) | 27 (4.5%) | 3 (5.5%) | 0 (0.0%) | |
| Total gastrectomy and subtotal esophagectomy | 9 (1.3%) | 4 (0.7) | 2 (3.6%) | 3 (11.5%) | |
| Fundus resection | 1 (0.1%) | 1 (0.2%) | 0 (0.0%) | 0 (0.0%) | |
| Reconstruction | |||||
| Roux-en-Y with Pouch | 97 (14.5%) | 86 (14.7%) | 11 (20.4%) | 0 (0.0%) | 0.004 |
| Roux-en-Y without Pouch | 550 (82.5%) | 487 (83.0%) | 40 (74.1%) | 23 (88.5%) | |
| Billroth II | 7 (1.0%) | 6 (1.0%) | 1 (1.9%) | 0 (0.0%) | |
| Colon interposition | 10 (1.5%) | 5 (0.9%) | 2 (3.7%) | 3 (11.5%) | |
| Other | 3 (0.4%) | 3 (0.5%) | 0 (0.0%) | 0 (0.0%) | |
| LAD | |||||
| <D2 | 7 (1.1%) | 5 (0.9%) | 2 (3.8%) | 0 (0.0%) | 0.197 |
| ≥ D2 | 651 (98.9%) | 575 (99.1%) | 51 (96.2%) | 25 (100%) | |
| (y)pT | |||||
| 0 | 16 (2.4%) | 16 (2.7%) | 0 (0.0%) | 0 (0.0%) | <0.001 |
| 1 | 142 (21.4%) | 139 (23.8%) | 1 (1.9%) | 2 (7.7%) | |
| 2 | 82 (12.3%) | 80 (13.7%) | 2 (3.8%) | 0 (0.0%) | |
| 3 | 277 (41.7%) | 239 (40.9%) | 22 (41.5%) | 16 (61.5%) | |
| 4 | 147 (22.1%) | 111 (19.0%) | 28 (52.8%) | 8 (30.8%) | |
| (y)pN | |||||
| 0 | 306 (45.3%) | 289 (48.6%) | 11 (20.4%) | 6 (23.1%) | <0.001 |
| 1 | 110 (16.3%) | 101 (17.0%) | 3 (5.6%) | 6 (23.1%) | |
| 2 | 94 (13.9%) | 80 (13.4%) | 10 (18.5%) | 4 (15.4%) | |
| 3 | 165 (24.4%) | 125 (21.0%) | 30 (55.6%) | 10 (38.5%) | |
| M | |||||
| M0 | 521 (86.7%) | 466 (88.6%) | 36 (73.5%) | 19 (73.1%) | 0.006 |
| M1 | 71 (11.8%) | 52 (9.9%) | 13 (26.5%) | 6 (23.1%) | |
| Mx | 9 (1.5%) | 8 (1.5%) | 0 (0.0%) | 1 (3.8%) | |
| UICC Stage | |||||
| I | 188 (28.7%) | 185 (32.1%) | 1 (1.9%) | 2 (7.7%) | <0.001 |
| II | 176 (26.9%) | 161 (28.0%) | 9 (17.3%) | 6 (23.1%) | |
| III | 205 (31.3%) | 164 (28.5%) | 29 (55.8%) | 12 (46.2%) | |
| IV | 71 (10.9%) | 52 (9.0%) | 13 (25.0%) | 6 (23.1%) | |
| (y)pT0 | 14 (2.1%) | 14 (2.4%) | 0 (0.0%) | 0 (0.0%) | |
| Lauren Subtype | |||||
| Diffuse | 211 (52.0%) | 174 (48.7%) | 33 (84.6%) | 4 (40.0) | <0.001 |
| Intestinal | 160 (39.4%) | 153 (42.9%) | 3 (7.7%) | 4 (40.0) | |
| Mixed | 35 (8.6%) | 30 (8.4%) | 3 (7.7%) | 2 (20%) | |
| Neoadjuvant therapy | |||||
| CTx | 0.350 | ||||
| PLF | 30 (10.4%) | 27 (10.8%) | 3 (11.5%) | 0 (0.0%) | |
| MAGIC | 59 (20.4%) | 49 (19.6%) | 7 (26.9%) | 3 (23.1%) | |
| FLOT | 113 (39.1%) | 102 (40.8%) | 6 (23.1%) | 5 (38.5%) | |
| Unknown | 47 (16.3%) | 41 (16.4%) | 5 (19.2%) | 1 (7.7%) | |
| Other | 4 (1.4%) | 3 (1.2%) | 1 (3.8%) | 0 (0.0%) | |
| RCTx | 36 (12.3%) | 28 (11.2%) | 4 (15.4%) | 4 (30.8%) | |
| Clavien–Dindo | |||||
| No complications | 323 (50.3%) | 295 (52.2%) | 20 (38.5%) | 8 (32.0%) | 0.194 |
| 1 | 76 (11.8%) | 65 (11.5%) | 9 (17.3%) | 2 (8.0%) | |
| 2 | 89 (13.9%) | 80 (14.2%) | 5 (9.6%) | 4 (16.0%) | |
| 3a | 63 (9.8%) | 52 (9.2%) | 7 (13.5%) | 4 (16.0%) | |
| 3b | 62 (9.7%) | 49 (8.7%) | 8 (15.4%) | 5 (20.0%) | |
| 4a | 9 (1.4%) | 8 (1.4%) | 1 (1.9%) | 0 (0.0%) | |
| 4b | 4 (0.6%) | 3 (0.5%) | 1 (1.9%) | 0 (0.0%) | |
| 5 | 16 (2.5%) | 13 (2.3%) | 1 (1.9%) | 2 (8.0%) | |
Continuous data shown as mean±SD, frequency data reported as absolute numbers and percentages.
CTx, Chemotherapy; GEJ, Gastroesophageal junction; LAD, Lymphadenectomy; RCTx, Chemoradiation; UICC, Union internationale contre le cancer.